<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03686787</url>
  </required_header>
  <id_info>
    <org_study_id>LSSC-TA-CB-ASDS</org_study_id>
    <nct_id>NCT03686787</nct_id>
  </id_info>
  <brief_title>Oral Tranexamic Acid and Laser for Treatment of Melasma</brief_title>
  <official_title>The Efficacy of Oral Tranexamic Acid and a 1927 nm Diode Laser in Patients With Melasma. A Prospective Randomized Split Face Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laser and Skin Surgery Center of New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dermatology &amp; Laser Surgery Center, Houston, TX</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laser and Skin Surgery Center of New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid and 1927 diode laser non-ablative fractionated laser for the treatment of
      Melasma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seeking healthy non-smoking male and female volunteers of all skin types of age 18 to 50 with
      moderate melasma or severe melasma. Participants will receive up to 5 monthly laser
      treatments to half the face and need to take a pill twice a day for 4 months. Follow up
      visits are required 1 month, 3 months and 6 months after the final treatment. Compensation of
      up to $150 will be provided based on completed visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Healthy, non-smoking</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mMASI (Modified Melasma Area and Severity Index)</measure>
    <time_frame>16 weeks</time_frame>
    <description>The difference between mMASI at week 0 and mMASI at week 16</description>
  </primary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Melasma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>A split face study of oral tranexamic acid in combination with laser treatment</description>
    <other_name>1927 nm nonablative laser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 18 to 50 Skin types I through VI (all skin types) Moderate or severe melasma

        Exclusion Criteria:

        Pregnant or nursing women Current use of hormonal birth control medication or any hormonal
        therapy Use of topical steroids within 1 month of study enrollment Use of topical
        hydroquinone within 3 months of study enrollment History of laser or dermabrasion to the
        face within 6 months of study enrollment Regular use of tanning parlors Occupation
        involving primarily outdoor activities Current treatment with blood thinning medications
        History of thrombosis or thrombophilia History of thromboembolic disease, such as deep vein
        thrombosis, pulmonary embolism and/or cerebral thrombosis Family history of thromboembolic
        disease History of stroke History of &gt;2 spontaneous abortions History of kidney dysfunction
        History of cancer Smoking Significant cardiovascular or respiratory disease (end-stage
        congestive heart failure or chronic obstructive pulmonary disease) History of subarachnoid
        hemorrhage History of acquired disturbances of color vision Known allergy to tranexamic
        acid As per the investigator's discretion, any physical or mental condition which might
        make it unsafe for the subject to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jennifer Moreno</last_name>
    <phone>212-686-7306</phone>
    <phone_ext>608</phone_ext>
    <email>jmoreno@laserskinsurgery.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Moreno</last_name>
      <phone>212-686-7306</phone>
      <phone_ext>608</phone_ext>
    </contact>
    <investigator>
      <last_name>Roy G Geronemus, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mitalee Christman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology &amp; Laser Surgery Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LaCresha Jackson</last_name>
      <phone>713-900-3900</phone>
      <email>lacresha@dermlasersurgery.com</email>
    </contact>
    <investigator>
      <last_name>Paul Friedman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Suggs, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.laserskinsurgery.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>September 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2018</study_first_posted>
  <last_update_submitted>September 25, 2018</last_update_submitted>
  <last_update_submitted_qc>September 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melasma</keyword>
  <keyword>chloasma</keyword>
  <keyword>tranexamic acid</keyword>
  <keyword>nonablative laser resurfacing</keyword>
  <keyword>sunscreen</keyword>
  <keyword>hyperpigmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

